IFNG and rheumatoid arthritis: For instance, JAK inhibitors have been primarily designed to suppress IFN-γ-induced activation of fibroblasts, thereby reducing their antigen-presenting capacity and mitigating autoreactive T cell activation in autoimmune diseases like RA 33.